Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search


Aqemia is an AI and quantum computing startup company working within the drug discovery sector of the pharmaceutical industry.

Aqemia is an Ile-de-France-based company founded in 2019 using in silico machine learning methods to discover and develop new drugs. The Aqemia generative artificial intelligence (AI) creates molecular compounds and predicts the molecules' interactions as pharmaceutical compounds within specific patients. Initially, Aqemia was developed at École Normale Supérieure Paris. However, it became a spin-off company in 2019 when it was formally founded by Maximilien Levesque, the current CEO, and Emmanuelle Martiano, the current COO.

École Normale Supérieure Paris

École Normale Supérieure Paris is considered a selective and prestigious graduate school located in Paris, France. Maximilien Leveque was a university professor teaching quantum mechanics and theoretical chemistry from 2014 to 2017 before teaching machine learning from 2017 to 2020. During Leveque's career at École Normale Supérieure, he was a research group leader (2014-2020), where he developed the technology for Aqemia.


October 17, 2019
Aqemia announces €1 million pre-seed round to disrupt the drug discovery market.

"With its first financing round, the company is looking to recruit the first members of its team. Specifically, CEO Levesque and COO Emmanuelle Martiano want to hire in silico drug hunters, software developers, and experts in generative artificial intelligence."

July 2019
Aqemia raises a $1,900,000 seed round from Elaia Partners.

Funding rounds


Further Resources


Aqemia and Servier announce AI and quantum physics-drive drug discovery collaboration in immuno-oncology

PR Newswire


December 16, 2021


Golden logo
By using this site, you agree to our Terms & Conditions.